Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Virtual Healthcare Made Easy. Here’s How.

Mednow Inc. ( TSX-V.MNOW , OTCMKTS: MDNWF , Forum ) is a healthcare technology company offering virtual access with exceptional care. It provides virtual care with convenience and through an interdisciplinary approach to healthcare that is focused on the patient experie...
Dave Jackson | December 7, 2021 |

Analyst Believes Biopharma's Alzheimer's Treatment Could Be Superior to Biogen's

How this company's Alzheimer's therapeutic compares to an advanced-stage competitor is outlined in a Dawson James Securities note. In a Dec. 2 research note, Dawson James Securities analyst Jason Kolbert purported that Anavex Life Sciences Corp.'s (AVXL:NASDAQ) ANAV...
Streetwise Reports | December 11, 2019 |

Acceleron Shares Open 50% Higher on Phase 2 PAH Trial Data

Acceleron Pharma's shares established a new 52-week high after the company reported that sotatercept achieved both primary and secondary endpoints in the Phase 2 PULSAR study in patients with pulmonary arterial hypertension. After U.S. markets closed for trading ye...
Streetwise Reports | January 29, 2020 |

CytoSorbents Shares Trade 20% Higher as FDA Grants CytoSorb EUA for COVID-19

Shares of CytoSorbents traded higher setting a new 52-week intraday high price after the company reported that the FDA granted emergency use authorization for CytoSorb for use in patients with COVID-19. Critical care immunotherapy company CytoSorbents Corp....
Streetwise Reports | April 14, 2020 |

MyoKardia Shares Get a Jolt from Positive Phase 3 HCM Clinical Trial Results

Shares of MyoKardia traded 60% higher, setting a new 52-week high price, after the company reported that it met all primary and secondary endpoints in the Phase 3 EXPLORER study of mavacamten in treatment of obstructive hypertrophic cardiomyopathy. Clinical-...
Streetwise Reports | May 12, 2020 |

Translate Bio and Sanofi Expand Partnership to Develop mRNA Vaccines

Translate Bio shares traded 45% higher reaching a new 52-week high after the company reported that it is expanding its collaboration with Sanofi Pasteur to develop mRNA vaccines across all infectious disease areas. Clinical-stage messenger RNA (mRNA) therapeutics c...
Streetwise Reports | June 24, 2020 |

The 'Virus' Technology That Kills Coronavirus Plus Lots of Other Pathogens

TOMI Environmental Solutions Inc.'s (TOMZ:OTCQB) products kill pathogens—safely and effectively. Not just the coronavirus: Ebola, MERS, C. diff spores, sepsis, norovirus, anthrax, Staphylococcus, MRSA, Legionnaire's and Zika. The kill list also includes food borne illnes...
Streetwise Reports | February 19, 2020 |

INmune Bio Targeting Cancer, Alzheimer's and NASH Simultaneously

We are initiating coverage on INmune Bio Inc. (INMB:NASDAQ) . According to the company, INmune is "Reprogramming the Innate Immune System for the Treatment of Diseases." On the surface, this sounds like a fairly standard biotech tagline, but there's a more here than me...
Streetwise Reports | December 5, 2019 |